+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID05569772

Study of Semaglutide Injections to Prevent Type 2 Diabetes in Women with Recent Gestational Diabetes and Glucose Intolerance

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-09-15

252

Participants Needed

13

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying women with a recent history of gestational diabetes GDM who have persistent glucose intolerance shortly after giving birth. These women are at high risk of developing type 2 diabetes T2DM, with about half developing it within five years. The study aims to evaluate whether using semaglutide, a long-acting GLP-1 agonist, can reduce the long-term risk of developing T2DM compared to placebo. This study is a phase 3, double-blind, randomized controlled trial conducted in multiple centers. Participants are randomly assigned to receive either semaglutide or a placebo once weekly by injection, alongside lifestyle measures. The semaglutide dose is gradually increased over eight weeks to a maintenance dose of 1 mg per week. The treatment period can last up to three years. After stopping the intervention, participants will undergo a 75g oral glucose tolerance test OGTT 3 to 6 months later. Randomization considers body mass index categories at early postpartum. Throughout the study, participants will have regular assessments including blood tests for glucose, HbA1c, insulin sensitivity, and beta-cell function. Researchers will also measure body weight, body composition, blood pressure, heart rate, lipid profiles, and metabolic syndrome prevalence. Patient-reported outcomes such as quality of life, depression, anxiety, treatment satisfaction, sleep quality, and food security will be collected. Health economic measures and biomarker analyses will also be performed. The primary outcome is the development of type 2 diabetes by 160 weeks, with continued follow-up up to 184 weeks.

CONDITIONS

Brief Title

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Research Team

K

Katrien Benhalima, MD PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here